Downloads and Tools

•  Article PDF
  1.16 MB PDF document

This is an open access article.
Print this page Email this page

Recipient's Email:

---

Article Citation

RIS
MARC (XML)
FULL CITATION (TXT)

---

Share on Facebook

Authors: Yulan Cheng, Srinivasan Senthamizhchelvan, Rachana Agarwal, Gilbert M. Green, Ronnie C. Mease, George Sgouros, David L. Huso, Martin G. Pomper, Stephen J. Meltzer and John M. Abraham

Yulan Cheng

Department of Medicine; The Johns Hopkins School of Medicine; Baltimore, MD USA

Srinivasan Senthamizhchelvan

Department of Radiology; The Johns Hopkins School of Medicine; Baltimore, MD USA

Rachana Agarwal

Department of Medicine; The Johns Hopkins School of Medicine; Baltimore, MD USA

Gilbert M. Green

Department of Radiology; The Johns Hopkins School of Medicine; Baltimore, MD USA

Ronnie C. Mease

Department of Radiology; The Johns Hopkins School of Medicine; Baltimore, MD USA

George Sgouros

Department of Radiology; The Johns Hopkins School of Medicine; Baltimore, MD USA

David L. Huso

Department of Molecular and Comparative Pathobiology; The Johns Hopkins School of Medicine; Baltimore, MD USA

Martin G. Pomper

Department of Radiology; The Johns Hopkins School of Medicine; Baltimore, MD USA

Stephen J. Meltzer

Corresponding author: smeltzer@jhmi.edu
Department of Medicine; The Johns Hopkins School of Medicine; Baltimore, MD USA

John M. Abraham

Corresponding author: jabrah14@jhmi.edu
Department of Medicine; The Johns Hopkins School of Medicine; Baltimore, MD USA

Abstract:
The search for new therapeutic agents that are effective against cancer has been difficult and expensive. The activity of anticancer candidate agents against human cancer-derived cell lines in immunocompromised mice is an important tool in this search. Because ATP is a naturally occurring small molecule, its radiolabeled form poses many advantages as a potential anticancer therapeutic agent. We previously found that a single, low-dose intravenous injection of [³²P]ATP inhibited the growth of xenografted tumors in nude mice for up to several weeks. The current study describes the biodistribution and the results and advantages of multi-dose administration of this potential drug. Future studies should investigate the mechanism involved in the possible use of [³²P]ATP as a cytotoxic agent that homes naturally to the tumor microenvironment.

Received: February 29, 2012; Accepted: March 8, 2012; Published Online: May 15, 2012

Preview: